Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yubao Wang (NPI 1306942644)

Field	Value
Entity Type	Individual
Organization	Yubao Wang
Address	177 La Casa Via Ste 390
City	Walnut Creek
State	CA
ZIP	94598
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 15, 2006

Payer Source	Total Paid
Medicare	$612K
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology Physician with an NPI enumerated on 2006-09-15 (~20 years ago), indicating long tenure in practice that likely supports an established infusion and outpatient oncology workflow. The top Medicare codes and the presence of both outpatient E/M (99214, 99215, 99213) and inpatient E/M codes (99223, 99233, 99232) in the top 25 suggest the provider mixes clinic-based infusion services with hospital/observation care encounters.

Medicare revenue is concentrated: total Medicare revenue is $612K and the precomputed top 3 Medicare codes account for 83.3% of that Medicare revenue. In particular, J9271 alone represents $438.6K (73.4% of Medicare revenue) from 10.2K claims with an average paid/claim of $43, which shows extreme reliance on a single drug product for the provider’s Medicare receipts.

Payer mix is effectively single-payer in this dataset: Medicare revenue is $612K while there is no Medicaid billing on file (none below). This means the provider’s publicly visible activity in this platform is driven entirely by Medicare, so analyses of Medicaid exposure or dual-eligible billing patterns are not supported by the data.

The code mix and volumes indicate an infusion-centric practice model: high-volume J9271 (pembrolizumab) billing at 10.2K claims paired with chemotherapy administration codes such as 96413 (217 claims, $20.6K revenue, $95 avg paid/claim) and add-on infusion codes like 96417 and 96415 point to routine in-office or clinic-based systemic therapy administration. Office E/M activity (99214: 362 claims, $32.9K revenue; 99215: 124 claims, $16.6K revenue) supports that the practice couples infusion treatments with moderate- to high-complexity outpatient visits.

Competitive standing across codes is mixed: J9271 generates the bulk of revenue but ranks #1157 of 1841 nationally (36th percentile) and is labeled “typical, unremarkable volume for this code,” so the provider is not a national leader for pembrolizumab volume despite revenue concentration. In contrast, office E/M codes such as 99214 (rank #79446 of 479517, 83th percentile, typical) and 99215 (rank #22981 of 145531, 84th percentile, typical) sit at higher percentiles, indicating relatively stronger performance on clinic visit volume versus peers.

There is an operational mismatch between revenue concentration and national rank: although J9271 accounts for $438.6K (73.4% of Medicare revenue), the provider’s rank for that code (36th percentile) is described as typical/unremarkable, which suggests high financial dependency on a drug reimbursement stream without corresponding above-average national volume leadership. This pattern raises sensitivity of overall revenue to changes in utilization or reimbursement for that single product.

Service breadth is evident but skewed: beyond high-revenue infusion codes, the listing includes procedural chemo administration codes (96402, 96411, 96417), infusion-related CPTs (96365, 96367, 96375), and care management code 99490, indicating the practice delivers a range of systemics and associated care coordination. However, many of these supporting codes are clustered at modest revenue shares (each under 4% of Medicare revenue), reinforcing that ancillary services complement but do not rival the dominant drug revenue driver.

From a risk/analysis perspective for payers or contracting teams, the provider represents a stable, long-tenured oncology practice with concentrated Medicare exposure: $612K total Medicare revenue with no Medicaid claims on file, a heavy dependence on J9271 at $438.6K, and generally typical national volume positions across most reported codes. Contracting, utilization review, and network planning should focus on pembrolizumab usage patterns and site-of-service infusion arrangements given the revenue concentration and the provider’s combined outpatient and inpatient E/M footprint.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

35 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,200	$40	$438.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	360	$90	$32.9K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	200	$130	$26K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	220	$100	$20.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	120	$130	$16.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	250	$60	$15.6K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	60	$120	$6.6K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	30	$160	$4.8K
99443	N/A	70	$70	$4.7K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	80	$50	$3.9K

Showing 1–10 of 35

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 35 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. California Distribution

Yubao Wang — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. state median

35 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	140	13,100	$40	$653.5K
J3490	14	320	80	$190	$49.2K
96413	15	620	170	$120	$26.9K
99233	347	11,530	120	$100	$26.2K
99490	130	1,060	210	$50	$25.8K
99214	332	37,970	120	$90	$23.2K
J9217	9	320	130	$130	$22.1K
99232	582	12,280	90	$70	$16.3K
99215	138	15,360	50	$130	$14.4K
99213	331	34,660	80	$70	$13.2K

Showing 1–10 of 35

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yubao Wang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lovelace Health System, LLC	NM	General Acute Care Hospital	$0	$57.7M
Lovelace Health System LLC	NM	General Acute Care Hospital	$0	$45.2M
Southwest Medical Associates, LLC	NM	General Practice Physician	$0	$41.4M
Lovelace Health System, LLC	NM	General Acute Care Hospital	$0	$31.2M
John Muir Physician Network	CA	General Practice Physician	$0	$27.1M
Lovelace Health System LLC	NM	General Acute Care Hospital	$0	$20.1M
Roger Goldberg	CA	Retina Specialist (Ophthalmology) Physician	$4.6M	$0
Michael Sherman	CA	Hematology & Oncology Physician	$3.9M	$0
Rajiv Nagesetty	CA	Vascular Surgery Physician	$3.6M	$0
Christianne Wa	CA	Retina Specialist (Ophthalmology) Physician	$3.5M	$0

Nearby Providers

Other providers in the same ZIP code as Yubao Wang, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bhpn, LLC	CA	Case Management Agency	$0	$350.7M
Easterseals Northern California	CA	Behavior Analyst	$0	$50.1M
John Muir Health	CA	General Acute Care Hospital	$0	$32.4M
Bay Area Retina Associates	CA	Retina Specialist (Ophthalmology) Physician	$0	$30.4M
Aspen Surgery Center, LLC	CA	Ambulatory Surgical Clinic/Center	$5.7M	$2M
Sequoia Surgical Center LP	CA	Ambulatory Surgical Clinic/Center	$2.6M	$3.8M
Min-wei Lee	CA	Dermatology Physician	$390.1K	$5.1M
Patrick Gonzales	CA	Vascular & Interventional Radiology Physician	$2.7M	$0
Tushar Ranchod	CA	Retina Specialist (Ophthalmology) Physician	$2.6M	$0
Subhransu Ray	CA	Retina Specialist (Ophthalmology) Physician	$2.3M	$0

Yubao Wang — Billing Profile & Reimbursement Data

Sign up for Yubao Wang — Billing Profile & Reimbursement Data policy alerts

Yubao Wang — Billing Profile & Reimbursement Data

Sign up for Yubao Wang — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References